Pinakin Bhakta, MD
Internal Medicine · Glendale, AZNPI 1760438618
Payments from drug & device makers
Across 209 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$845
- Lilly USA, LLC$592
- Amgen$516
- Astellas Pharma US Inc$317
- Novo Nordisk$247
- AbbVie$238
- plus $2K from 29 others
What the payments were for
- Consulting fees$1754%
- Food & beverage$4,01493%
- Education$1503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $845 |
| Lilly USA, LLC | 35 | $592 |
| Amgen | 15 | $516 |
| Astellas Pharma US Inc | 6 | $317 |
| Novo Nordisk | 11 | $247 |
| AbbVie(2 entities) | 12 | $238 |
| Pfizer | 12 | $210 |
| Boehringer Ingelheim | 9 | $179 |
| Abbott | 9 | $176 |
| Amarin Pharma, Inc. | 10 | $144 |
| GSK | 6 | $115 |
| Novartis | 4 | $77 |
| Merck | 4 | $75 |
| Nestle Healthcare Nutrition Inc. | 3 | $67 |
| Sanofi-aventis U.S. LLC | 5 | $66 |
| Bayer | 3 | $56 |
| Exact Sciences | 2 | $46 |
| Edwards Lifesciences | 1 | $44 |
| Dexcom, Inc. | 2 | $39 |
| Johnson & Johnson(2 entities) | 2 | $31 |
| Nevro Corp. | 1 | $27 |
| Boston Scientific | 1 | $22 |
| Globus Medical | 1 | $21 |
| Lucid Diagnostics Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| SK Life Science, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$297
- Veozah$125
- Xultophy 100/3.6$119
- BREZTRI$117
How this compares
$4,338 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $114,416 |
| JardianceEmpagliflozin | 47 | $72,827 |
| FarxigaDapagliflozin Propanediol | 46 | $56,988 |
| EliquisApixaban | 51 | $52,639 |
| TrulicityDulaglutide | 31 | $45,266 |
| RybelsusSemaglutide | 19 | $27,062 |
| ProliaDenosumab | 15 | $25,684 |
| MounjaroTirzepatide | 21 | $24,580 |
| EntrestoSacubitril/Valsartan | 21 | $22,110 |
| TradjentaLinagliptin | 12 | $16,044 |
| JanuviaSitagliptin Phosphate | 14 | $16,042 |
| Spiriva RespimatTiotropium Bromide | 15 | $9,086 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,823 |
| Atorvastatin Calcium | 586 | $5,730 |
| Levothyroxine Sodium | 361 | $3,939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $247 | $141,478110 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $179 | $97,95774 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $592 | $69,84552 claims |
| AstraZenecaFarxiga, Symbicort | $845 | $63,81163 claims |
| PfizerEliquis | $210 | $52,63951 claims |
| AmgenProlia | $516 | $25,68415 claims |
| NovartisEntresto | $77 | $22,11021 claims |
| MerckJanuvia | $75 | $16,04214 claims |
| Sanofi-aventis U.S. LLCLantus, Soliqua 100-33 | $66 | $6,71327 claims |
| AbbVieSynthroid | $238 | $1,78516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Glendale
- Gurdev SinghGlendale$649K
- Michael CastroGlendale$156K
- Christine HarterGlendale$127K
- Yessica SachdevaMesa$13.7M
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.